Companion Diagnostics Market Share

1. GLOBAL COMPANION DIAGNOSTICS (CDX) MARKET: FOCUS ON TECHNOLOGY, INDICATION, COUNTRY-WISE ANALYSIS, REGULATORY FRAMEWORK, AND COMPETITIVE LANDSCAPE - ANALYSIS AND FORECAST, 2018-2025 Key Questions Answered in the Report: • What are the major market drivers, challenges, and opportunities in the global companion diagnostics market? MORE THAN 50 COMPANIES RESEARCHED ACROSS THE VALUE CHAIN • What are the underlying structures resulting in the emerging trends within the companion diagnostics industry? • What was the market value of the leading segments and sub-segments of the global companion diagnostics systems market in 2017? • How will each segment of the global companion diagnostics market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2025? METICULOUS COMPILATION OF MORE THAN 700 RESEARCH HOURS • Whataretheinfluencingfactorsthatmayaffectthemarketshareofthekeyplayers? • How will the industry evolve during the forecast period 2018- 2025? • What are the key developmental strategies which are being implemented by the key players to sustain in this competitive market? • What are the key technologies in the companion diagnostics market? What are the major benefitsofeachtechnology? • How has the market been segmented on the basis of indication? Which indication is dominating the global companion diagnostics market and its reason? EXCLUSIVE INSIGHTS FROM IN-DEPTH EXPERT INTERVIEWS • What is the market share of the companies by CDx technologies which include Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next Generation Sequencing (NGS), and Polymerase Chain Reaction (PCR)? • Who are the key manufacturers in companion diagnostics market and what are their contributions? • What is the scope of each companion diagnostic technology in North America, Europe, andAsia-Pacific? CONTAINS 48 MARKET DATA TABLES AND 172 FIGURES SPREAD ACROSS 297 PAGES • What are the key regulatory implications in developed and developing regions for companion diagnostics? • What is the growth potential of companion diagnostics in each region? • Which companion diagnostic technology is having the most promising growth and in which indication type? 1 www.bisresearch.com  sales@bisresearch.com

2. TABLE OF CONTENTS • ClassificationofCompanionDiagnostics(CDx) • CDx in a Historical Perspective • Constituents for Companion Diagnostics (CDx) Development • SignificantApplicationsofCompanionDiagnostics (CDx) • Companion Diagnostics (CDx): Future Potential COMPANY PROFILES • Overview • Abbott Laboratories • Agilent Technologies, Inc. • ARUP Laboratories • bioMérieux SA • Danaher Corporation • F.Hoffmann-LaRocheAG • Illumina, Inc. • Invivoscribe Technologies, Inc. • MolecularMD Corporation • Myriad Genetics, Inc. • QIAGEN N.V. • ThermoFisherScientificInc. • ArcherDx, Inc. • Exosome Diagnostics, Inc. • NeoGenomics, Inc. • MDxHealth, Inc. • NanoString Technologies, Inc. • Overview • Iceberg Analysis • Impact Analysis • Market Drivers • Market Restraints • Opportunities within the Market MARKET OVERVIEW • Key Strategies and Developments • Joint Ventures, Partnerships, and Collaborations • Product Approvals • Acquisitions • Product Launches and Other Developments • Market Share Analysis • Growth Share Analysis MARKET DYNAMICS COMPETITIVE INSIGHTS • Legal Requirements and Framework by the FDA • Legal Requirements and Framework by the EMA • Legal Requirements and Framework by the MHLW REGULATORY FRAMEWORK RESEARCH SCOPE & METHODOLOGY • Assumptions & Limitations for Market Size Calculations • Market Overview • Report Scope • Companion Diagnostics Market: Research Methodology GLOBAL COMPANION DIAGNOSTICS MARKET: ANALYSIS AND FORECAST • Overview • Polymerase Chain Reaction (PCR) • Immunohistochemistry (IHC) • In-situ Hybridization (ISH) • Next Generation Sequencing (NGS) GLOBAL COMPANION DIAGNOSTICS MARKET (BY TECHNOLOGY) GLOBAL COMPANION DIAGNOSTICS MARKET (BY INDICATION) • Overview • Lung Cancer • Breast Cancer • Colorectal Cancer • Stomach Cancer • Leukemia • Melanoma • Others • Non-Oncology Diseases GLOBAL COMPANION DIAGNOSTICS MARKET (BY REGION) • Overview • North America • Europe • Asia-Pacific • Rest-of-the-World VIEW COMPLETE TABLE OF CONTENTS 2 www.bisresearch.com  sales@bisresearch.com

3. LIST OF TABLES 23 Agilent Technologies, Inc.: Collaborations 1 Impact Analysis of Market Restraints 24 ARUP Laboratories: Collaboration 2 Impact Analysis of Market Opportunities 25 Mérieux SA: Approval 3 R&D Revenue of Major CDx Companies (as of FY2017) 26 Danaher Corporation: Collaborations and Partnership 4 PCR-Based Companion Diagnostics Manufacturers 27 F.Hoffmann-LaRocheAG:Collaborations, Agreements, and Partnerships 5 PCR-Based Companion Diagnostics Service Providers 28 F.Hoffmann-LaRocheAG:ProductApprovals 6 IHC-Based Companion Diagnostics Manufacturers 29 Illumina, Inc.: Collaborations, Agreements, and Partnerships 7 IHC-Based Companion Diagnostics Service Providers 30 Illumina, Inc.: Acquisition 31 Illumina, Inc.: Product Approval 8 ISH-Based Companion Diagnostics Manufacturers 32 Invivoscribe Technologies, Inc.: Product Approval 33 MolecularMD Corporation: Agreement and Partnership 9 ISH-Based Companion Diagnostics Service Providers 34 Invivoscribe Technologies, Inc.: Product Approval 10 NGS-Based Companion Diagnostics Manufacturers 35 Myriad Genetics, Inc.: Collaborations and Agreements 11 NGS-Based Companion Diagnostics Service Providers 36 Illumina, Inc.: Product Approval 12 Cancer Type- Incidence and Mortality 37 QIAGEN N.V.: Acquisition 13 Available Companion Diagnostic Tests for Lung Cancer 38 QIAGEN N.V.: Collaborations, Partnership, and Agreement 14 Available Companion Diagnostic Tests for Breast Cancer 39 QIAGEN N.V.: Product Approval 40 ThermoFisherScientificInc.:Collaborations, Partnership, and Agreement 15 Available Companion Diagnostic Tests for Colorectal Cancer 41 ThermoFisherScientificInc.:ProductApproval 16 Available Companion Diagnostic Tests for Stomach Cancer 42 ArcherDX, Inc.: Collaborations, Partnership, and Agreement 17 Available Companion Diagnostic Tests for Leukemia 43 Exosome Diagnostics, Inc.: Collaborations and Partnerships 18 Available Companion Diagnostic Tests for Melanoma 44 NeoGenomics, Inc.: Acquisition 45 NeoGenomics, Inc.: Collaboration and Agreement 19 Available Companion Diagnostics for Others 20 Abbott Laboratories: Partnerships, Agreements, and Collaborations 46 NeoGenomics, Inc.: Product Launch 47 MDxHealth, Inc.: Partnerships and Agreements 21 Abbott Laboratories: Product Approvals 48 NanoString Technologies, Inc.: Partnership, Collaboration and Agreement 22 Agilent Technologies, Inc.: Acquisition 3 www.bisresearch.com  sales@bisresearch.com

4. LIST OF FIGURES 1 Escalating Healthcare Expenditure, 2016-2020 25 Acquisition Share by Companies (January 2014- July 2018) 2 Impact of Market Drivers and Market Restraints, 2017 and 2025 26 Market Share Analysis for the Global Companion Diagnostics Market (2016) 3 Global Companion Diagnostics (CDx) Market Snapshot 27 Market Share Analysis for the Global Companion Diagnostics Market (2017) 4 Dominating Segments of Global Companion Diagnostics Market, 2017 and 2025 28 Growth Share Matrix for Global Companion Diagnostics Market (by Technology), 2017 5 Global Companion Diagnostics Market (by Technology), 2017 and 2025 29 Growth Share Matrix for Global Companion Diagnostics Market (by Indication), 2017 6 Global Companion Diagnostics Market (by Indication), 2017 and 2025 30 Growth Share Matrix for Global Companion Diagnostics Market (by Indication), 2018 and 2025 7 Global Companion Diagnostics Market (by Region), 2017 and 2025 31 Industy Attractieness (Porter’s Five Forces Analysis) 8 Growth Share Matrix for Global Companion Diagnostics Market (by Country), 2018 and 2025 32 Bargaining Power of Suppliers: Overall Impact 9 Market Statistics 33 Bargaining Power of Buyers: Overall Impact 10 Growth Share Matrix for Global Companion Diagnostics Market (by Indication), 2017 34 Threat of New Entrants: Overall Impact 11 ClassificationofCompanionDiagnostics(CDx) 35 Threat of Substitute Products: Overall Impact 12 Evolution of Companion Diagnostics (CDx) 36 Intensity of Competitive Rivalry: Overall Impact 13 Components Required to Develop Companion Diagnostics 37 FDA Guidelines for CDx Approval 38 Global Companion Diagnostics Market, 2017-2025 14 Applications of Companion Diagnostics (CDx) 39 Companion Diagnostics Market (by Technology) 15 Potential of Companion Diagnostics (CDx) 40 Global Companion Diagnostics Market (by Technology), 2017-2025 16 Market Dynamics 17 Iceberg Analysis 41 Global Companion Diagnostics Market (by PCR Technology), 2017-2025 18 Cancer Incidence by WHO Region (2012) per 100,000 42 Global Companion Diagnostics Market (by IHC Technology), 2017-2025 19 Fully Aligned Drug-Diagnostic Co-Development 43 Global Companion Diagnostics Market (by ISH Technology), 2017-2025 20 CDx Leakage for Oncology 21 Competitive Landscape (January 2014-July 2018) 44 Global Companion Diagnostics Market (by NGS Technology), 2017-2025 22 Share of Key Developments and Strategies (January 2014-July 2018) 45 Global Companion Diagnostics Market (by Indication), 2017-2025 23 Joint Venture, Partnership, and Collaboration Share by Companies (January 2014-July 2018) 46 Global Companion Diagnostics Market (by Lung Cancer), 2017-2025 24 Product Approval Share by Companies (January 2014-July 2018) 47 Total Market Size for Lung Cancer Companion 4 www.bisresearch.com  sales@bisresearch.com

5. LIST OF FIGURES Diagnostics (2017 and 2020) Indication), 2017-2025 48 Global Companion Diagnostic Market (by Breast Cancer), 2017-2025 68 The U.S. Companion Diagnostics Market, 2017- 2025 49 Total Market Size for Breast Cancer Companion Diagnostics (2017 and 2020) 69 Canada Companion Diagnostics Market, 2017- 2025 50 Global Companion Diagnostics Market (by Colorectal Cancer), 2017-2025 70 Overview of Reimbursement Policies across Europe 51 Total Market Size for Colorectal Cancer Companion Diagnostics (2017 and 2020) 71 Europe Companion Diagnostics Market, 2017- 2025 52 Global Companion Diagnostics Market (by Stomach Cancer), 2017-2025 72 Europe: Market Dynamics 73 Europe Companion Diagnostics Market (by Country), 2017-2025 53 Total Market Size for Stomach Cancer Companion Diagnostics (2017 and 2020) 74 Europe Companion Diagnostics Market (by Indication), 2017-2025 54 Global Companion Diagnostics Market (by Leukemia), 2017-2025 75 The U.K. Companion Diagnostics Market, 2017- 2025 55 Total Market Size for Leukemia Companion Diagnostics (2017 and 2020) 76 Germany Companion Diagnostics Market, 2017- 2025 56 Global Companion Diagnostics Market (by Melanoma), 2017-2025 77 France Companion Diagnostics Market, 2017- 2025 57 Total Market Size for Melanoma Companion Diagnostics (2017 and 2020) 78 Italy Companion Diagnostics Market, 2017-2025 58 Global Companion Diagnostics Market (by Others), 2017-2025 79 Spain Companion Diagnostics Market, 2017-2025 80 Rest-of-Europe Companion Diagnostics Market, 2017-2025 59 Total Market Size for Others Companion Diagnostics (2017 and 2020) 81 APAC Companion Diagnostics Market, 2017-2025 60 Global Companion Diagnostics Market (by Region), 2017 and 2025 82 APAC: Market Dynamics 83 APAC Companion Diagnostics Market (by Country), 2017-2025 61 Global Companion Diagnostics Market (by Region), 2017-2025 84 APAC Companion Diagnostics Market (by Indication), 2017-2025 62 Global Companion Diagnostics Market Share (by Region), 2017 85 China Companion Diagnostics Market, 2017-2025 63 Global Companion Diagnostics Market Share (by Region), 2025 86 Japan Companion Diagnostics Market, 2017-2025 64 North America Companion Diagnostics Market, 2017-2025 87 India Companion Diagnostics Market, 2017-2025 88 Australia Companion Diagnostics Market, 2017- 2025 65 North America: Market Dynamics 66 North America Companion Diagnostics Market (by Country), 2017-2025 89 Singapore Companion Diagnostics Market, 2017- 2025 67 North America Companion Diagnostics Market (by 90 Rest-of-APAC Companion Diagnostics Market, 5 www.bisresearch.com  sales@bisresearch.com

6. LIST OF FIGURES 2017-2025 116 Mérieux SA: SWOT Analysis 91 Rest-of-the-World Companion Diagnostics Market, 2017-2025 117 Danaher Corporation: Overall Product Portfolio 118 Danaher Corporation: Product Portfolio for Companion Diagnostics Market 92 TotalNumberofCompanyProfiles 93 Abbott Laboratories: Overall Product Portfolio 119 Danaher Corporation: Overall Financials, 2015- 2017 94 Abbott Laboratories: Product Portfolio for Companion Diagnostics Market 120 Danaher Corporation: Net Revenue (by Region), 2015-2017 95 Abbott Laboratories: Overall Financials, 2015- 2017 121 Danaher Corporation: Net Revenue (by Business Segment), 2015-2017 96 Abbott Laboratories: Revenue (by Segment), 2015-2017 122 Danaher Corporation: Global Presence 97 Abbott Laboratories: Revenue (by Region), 2015- 2017 123 Danaher Corporation: SWOT Analysis 124 F.Hoffmann-LaRocheAG:OverallProduct Portfolio 98 Abbott Laboratories: Global Presence 99 SWOT Analysis: Abbott Laboratories 125 F.Hoffmann-LaRocheAG:ProductPortfoliofor Companion Diagnostics Market 100 Agilent Technologies, Inc.: Overall Product Portfolio 126 F.Hoffmann-LaRocheAG:OverallFinancials, 2015-2017 101 Agilent Technology, Inc.: Product Portfolio for Companion Diagnostics Market 127 F.Hoffmann-LaRocheAG:NetRevenue(by Region), 2015-2017 102 Agilent Technologies, Inc.: Overall Financials, 2015-2017 128 F.Hoffmann-LaRocheAG:NetRevenue(by Business Segment), 2015-2017 103 Agilent Technologies, Inc.: Revenue (by Region), 2015-2017 129 F.Hoffmann-LaRocheAG:GlobalPresence 104 Agilent Technologies, Inc.: Revenue (by Segment), 2015-2017 130 F.Hoffmann-LaRocheAG:SWOTAnalysis 131 Illumina, Inc.: Overall Product Portfolio 105 Agilent Technologies, Inc.: Global Presence 132 Illumina, Inc.: Product Portfolio for Global Companion Diagnostics Market 106 Agilent Technologies, Inc. SWOT Analysis 107 ARUP Laboratories: Overall Product Portfolio 133 Illumina, Inc.: Overall Financials, 2015-2017 108 ARUP Laboratories: Product Portfolio for Companion Diagnostics Market 134 Illumina, Inc.: Net Revenue (by Region), 2015- 2017 109 ARUP Laboratories: SWOT Analysis 135 Illumina, Inc.: Net Revenue (by Business Segment), 2015-2017 110 Mérieux SA: Overall Product Portfolio 136 Illumina, Inc.: Global Presence 111 Mérieux SA: Product Portfolio for Companion Diagnostics Market 137 Illumina, Inc.: SWOT Analysis 112 Mérieux SA: Overall Financials, 2015-2017 138 Invivoscribe Technologies, Inc.: Overall Product Portfolio 113 Mérieux SA: Revenue (by Segment), 2015-2017 139 Invivoscribe Technologies, Inc.: Product Portfolio for Global Companion Diagnostics Market 114 Mérieux SA: Revenue (by Region), 2015-2017 115 Mérieux SA: Global Presence 6 www.bisresearch.com  sales@bisresearch.com

7. LIST OF FIGURES 140 Invivoscribe Technologies, Inc.: SWOT Analysis 157 ThermoFisherScientificInc.:OverallProduct Portfolio 141 MolecularMD Corporation: Overall Product Portfolio 158 ThermoFisherScientificInc.:ProductPortfoliofor Global Companion Diagnostics Market 142 MolecularMD Corporation: Product Portfolio for Global Companion Diagnostics Market 159 ThermoFisherScientificInc.:OverallFinancials, 2015-2017 143 MolecularMD Corporation: SWOT Analysis 160 ThermoFisherScientificInc.:NetRevenue(by Business Segment), 2015-2017 144 Myriad Genetics, Inc.: Overall Product Portfolio 145 Myriad Genetics, Inc.: Product Portfolio for Global Companion Diagnostics Market 161 ThermoFisherScientificInc.:NetRevenue(by Region), 2015-2017 146 Myriad Genetics, Inc.: Overall Financials, 2015, 2016, 2017 162 ThermoFisherScientificInc.:GlobalPresence 163 ThermoFisherScientificInc.:SWOTAnalysis 147 Myriad Genetics, Inc.: Net Revenue (by Business Segment), 2015, 2016, 2017 164 Global Companion Diagnostics Market Segmentation 148 Myriad Genetics, Inc.: Global Presence 165 Global Companion Diagnostics Market Research Methodology 149 Myriad Genetics, Inc.: SWOT Analysis 150 QIAGEN N.V.: Overall Product Portfolio 166 Primary Research 151 QIAGEN N.V.: Product Portfolio for Global Companion Diagnostics Market 167 Secondary Research 168 Data Triangulation 152 QIAGEN N.V.: Overall Financials, 2015-2017 169 Bottom-Up Approach (Segment-Wise Analysis) 153 QIAGEN N.V.: Net Revenue (by Business Segment), 2015-2017 170 Top-Down Approach (Segment-Wise Analysis) 154 QIAGEN N.V.: Net Revenue (by Region), 2015- 2017 171 Assumptions and Limitations 172 Considered Factors for Data Prediction and Modeling 155 QIAGEN N.V.: Global Presence 156 QIAGEN N.V.: SWOT Analysis 7 www.bisresearch.com  sales@bisresearch.com

8. 1 Research Scope & BIS Methodology 1.1 Scope of the Report The report constitutes of an in-depth study of the global companion diagnostics market, including a thoroughanalysisofthetypesofproductsforvariousdiseaseindicationsbydifferenttechnologies.The study also presents a detailed analysis of the market dynamics and the estimation of the market size over the forecast period 2018-2025. The scope of this report is focused on the companion diagnostic products fordifferentdiseaseindicationsthatarebasedonfourmajortechnologiesincludingImmunohistochemistry (IHC), In-situ Hybridization (ISH), Next Generation Sequencing (NGS), and Polymerase Chain Reaction (PCR), and their country-wise analysis. The market value may vary from (5-7) % as the data has been collectedfromdifferentsourcesattheregional-andcountry-level. The market analysis includes an in-depth examination of the key ecosystem players and key strategies and developments taking place in the market. However, the market estimation only includes the companion diagnostic manufacturers across the globe. Further, it includes the market dynamics (market drivers, opportunities, and challenges) and industry analysis. The purpose of the study is to gain a holistic view oftheglobalcompaniondiagnosticsmarketintermsofvariousfactorsinfluencingthemarket,including regulatory reforms and technological advancements. The market has been segmented into ‘disease indications’, ‘technologies’, and ‘regions’. The scope of this report is centered upon conducting a detailed study of the products allied with the companion diagnostics market. For products, which no real-time data was available in the public domain, personnel from the respective companieswerecontactedinordertogainvaluableinformationpertainingtotheproductindifferent regions and their corresponding price. This information was then used to estimate the global number for a particular product which was later validated by the industry experts. 1.2 BIS Research Market Research Methodology Theresearchmethodologydesignadoptedforthisspecificstudyincludesamixofdatacollectedfrom primary and secondary sources. Both primary sources (in-house experts, industry leaders, and market players) and secondary sources (a host of paid and unpaid databases) along with analytical tools have been used exhaustively to build the forecast and predictive models. Figure 1 BIS Research Market Research Methodology RESEARCH APPROACH PRIMARY RESEARCH SECONDARY RESEARCH 1. DATABASE FOR KEY INDUSTRY PARTICIPANTS (DKIP) PREPARATION STUDYING THE MARKET STRUCTURE The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various vendors providing technology solutions, associated service providers, and system integrators operatingin the targetedregions. E.g. CIO’s, VP, DirectorNew ProductDevelopment,Director–operations Mainly used to obtain key information about the industry’s value chain, the total pool of key players IDENTIFY MARKET, TECHNOLOGY AND COMPETITOR TRENDS 2. DISCUSSION GUIDE PREPARATION Understand market classification, and segmentation according to industry trends to the bottom-most level, regional markets, and key developments from both market- and technology-oriented perspectives A detailed questionnaire is shared with the primary respondent covering all the aspects related to the report topic 3. SCHEDULING AN APPOINTMENT Appointments are scheduled with CIO’s, VP – healthcare companies, Director with prior appointmentsand the discussionguide is shared with the primary respondentprior to the call INTEGRATE INFORMATION Integrate information within relevant documents to form launch pad for primary research 4. CALL EXECUTION A roundtable discussion is held with the KIP with the aim to gather first hand information about the technology,recent developmentsin the technologyand future outlook/ growthor decline VENDORS CONSULTANT RESELLERS 5. DOCUMENTATION POTENTIAL RESPONDENTS The interview is recorded and the information gathered in put on the drawing board with the informationcollectedthroughsecondary research. END USER MSP’s BIS Research Analysis 8 www.bisresearch.com  sales@bisresearch.com

9. Primary Data Sources The key data points taken from Primary Sources includes: • Validation and Triangulation of all the numbers and graphs • Validationofreportsegmentationandkeyqualitativefindings • Understanding the competitive landscape • Understanding and considering the market dynamics factors for various market segment and sub- segment • Validationofimpactanalysisofmacroandmicrofactorsindifferentcountries • Percentage split of individual markets for geographical analysis Secondary Data Sources The research study involves the usage of extensive secondary sources such as databases, company websites, and annual reports, among others. Thefollowingfigureexhibitskeysecondarydatasourcesconsideredinthisreport: Figure 2 Secondary Data Sources STOCK ANALYST WEBSITES COMPANY SOURCES Seeking Alpha Yahoo Finance Wiki Finance The Wall Street Journal Annual Reports Press Releases SEC Filings Investor Presentations Financial Disclosures SECONDARY DATA SOURCES GOVERNMENT AND REGULATORY SOURCES PUBLIC AND PRIVATE DATABASES Medline PubMed National Library of Medicine ProQuest Thin Database CMS Datasets Medicare Beneficiaries Database Oxon Epidemiology Hoovers One Source Factiva The Centre for Disease Control (CDC) The World Health Organization (WHO) The National Health Services (NHS) The National Center for Biotechnology Information (NCBI) The Food & Drug Administration of United States (U.S. FDA) BIS Research Analysis 9 www.bisresearch.com  sales@bisresearch.com

10. The key data points taken from secondary sources include: • Segmentation breakups, split-ups, and percentage shares • Data for market value • Key industry trends of the top players of the market • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation • Quantitative data for mathematical and statistical calculations Thefollowingfigureexhibitsdatatriangulationconsideredinthisstudy: Figure 3 Data Triangulation PRIMARY SOURCES SECONDARY SOURCES INTERVIEWS WITH: • R&D managers and product managers of the leading players in the industry • Top research organizations conducting research focused upon emerging technological advancements • SEC Filings of the leading market players SUPPLY SIDE • Company websites and detailed study of their product portfolio • Annual reports, investor presentations of the key players in the market INFORMATION SOURCED • Magazines, journals, white papers, press releases, news articles etc. DATA INTERVIEWS WITH: • Senior management of the leading companion diagnostics companies • Vice Presidents of in-vitro diagnostic companies • Top scientists and professors from leading research universities TRIANGULATION PRIMARY SOURCE DEMAND SIDE National Institute of Health(NIH), Center for Disease Control (CDC), Food Drug and Administration(FDA), World Health Organization (WHO), American Medical Association(AMA), PubMed, European business directory, and The Economist Intelligence Unit (EIU), among others SECONDARY SOURCE INFORMATION SOURCED Opportunities/ Challenges Market Size and Market Share Key Players Competitive Landscape Geographical Analysis Influencing Factors Market Estimates Market Trends BIS Research Analysis REQUEST FOR SAMPLE 10 www.bisresearch.com  sales@bisresearch.com